“Amend Surgical provides surgeons and their patients access to innovative bone grafting options,” said Jackson Streeter, M.D., Florida Institute CEO. “By developing and advancing bone grafts and other orthobiologics with enhanced regenerative capacity, surgery patients can identify, with guidance from their physicians, new options that can help them achieve the best possible surgical outcomes.”
Amend Surgical is focused on enhancing the healing and regenerative capacity of bone grafts, including allograft, xenograft tissues and synthetic materials. The company’s pipeline includes osteoinductive bone extracts, and will expand in the future to disruptive products based on discovery and development of therapeutic additives with tissue-specific regenerative characteristics.
“We are committed to advancing the science of orthobiologics by improving the healing capacity of bone grafts. The new funding agreement with the Florida Institute will allow Amend to rapidly expand our research and commercialization efforts on Biomimetic Bone which was licensed from the University of Florida in March 2017,” said Robby Lane, CEO of Amend Surgical.
Formed by the Florida Legislature in 2007, the Florida Institute for the Commercialization of Public Research is a non-profit organization that works collaboratively with the technology licensing and commercialization offices of Florida’s state universities and private research institutions to leverage a research base worth more than $2.5 billion and form investable companies that create clean jobs in new industries that are driving the global economy. With funding from the State of Florida through the Department of Economic Opportunity, and through mentors, advisors and donors, the Florida Institute provides company building services, and seed funding through the Florida Technology Seed Capital Fund, to promising Florida startups. Sixty-nine companies have been funded to date, and the Florida Institute’s economic impact through June 30, 2016, in the State of Florida was $630 million.
Amend Surgical is a product development company offering differentiated biologic solutions for surgeons, medical device manufacturers and distributors globally. Amend is targeting the bone graft substitute market with licensed, patented, technology and is focused on spine, orthopedic and dental indications. The R&D pipeline includes products loaded with antibiotics and natural bone morphogenic proteins. Additionally, Amend is commercializing a novel Biomimetic Bone technology licensed from the University of Florida that offers the hope for a synthetic graft with load bearing capability and osteostimulative properties. Amend currently manufactures and distributes the only demineralized bone-bioactive glass combination product approved by the U.S. Food and Drug Administration. NanoFUSE Bioactive Matrix uniquely combines the osteoinductive capabilities of demineralized allograft bone with the osteostimulative properties of 45S5 bioactive glass.